Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2025. Mr. Drysdale's firesi.
- 05/14/2025
|
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD. The patent, which is expected to provide exclusivity until 2041, includes cla.
- 05/08/2025
|
Cybin to Participate at the 28th Annual Milken Institute Global Conference
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 28th Annual Milken Institute Global Conference on a panel entitled “The Global Landscape and Opportunities for Medical Breakthroughs.” T.
- 05/01/2025
|
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced additional strategic partnership agreements (“SPAs”), bringing the total to 18 clinical sites engaged to advance Cybin's multinational Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD.
- 04/23/2025
|
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. “Prepara.
- 04/21/2025
|
Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for Cybin Inc. (CYBN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 03/04/2025
|
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet
- The consensus price target hints at a 988.7% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 02/17/2025
|
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its third quarter ended December 31, 2024, and recent business highlights. “As we advance our lead clinical programs, CYB003 and CYB004, our focus in 2025 remains on continued.
- 02/10/2025
|
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 952.2% in Cybin Inc. (CYBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/30/2025
|
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“SPA”) with Segal Trials in furtherance of Cybin's multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of Major De.
- 01/15/2025
|
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to provide a year-end summary of its key accomplishments in 2024 and upcoming milestones for 2025. “In 2024, we made significant progress toward our goal of transforming the mental health treatment landscape,” said Dou.
- 01/13/2025
|
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025. The fireside chat.
- 01/09/2025
|
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting taking place December 8-11, 2024, in Phoenix, Arizona. The data presented include 12-month efficacy result.
- 12/10/2024
|
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, and Amir Inamdar, MBBS, DNB (Psych), FFPM, Cybin's Chief Medical Officer, will participate in the Water Tower Research Fireside Chat Series taking place.
- 12/04/2024
|
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in development for the potential adjunctive treatment of major depressive disorder (“MDD”). As previ.
- 11/18/2024
|
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer,.
- 11/14/2024
|
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of PARADIGMTM, its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the.
- 11/13/2024
|
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 2024 Milken Institute Future of Health Summit on a panel entitled “The Next Frontier in Mental Health Research.” “We share the.
- 10/31/2024
|
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the Company's CYB005 phene.
- 10/24/2024
|
Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +
- The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 11th - 17th, aiming to inspire discussion and provide investment ideas. AST SpaceMobile is highly volatile but has strong potential in satellite broadband services according to Josh Arnold who initiated a strong buy rating. Equinor ASA's acquisition of Ørsted's stake and its strong cash flow make it an intriguing investment for Carlos Bonfiglio in the renewable energy sector.
- 10/18/2024
|
Cybin: Top Value Psychedelic Stock
- Cybin is a promising value investment, with advanced clinical trials and strong institutional support, poised to disrupt mental health treatment. Cybin's proprietary drugs, CYB003 for depression and CYB004 for anxiety, show groundbreaking efficacy and shorter treatment time, enhancing patient and provider convenience. Cybin's trial results, robust IP portfolio, and solid financials de-risk its path to FDA approval, with a market cap significantly lower than competitors.
- 10/15/2024
|
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in the Water Tower Research Fireside Chat Series taking place on Tuesday, October 8, 2024, at 3:00 p.m. ET. The fireside chat will be ho.
- 10/03/2024
|
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the appointment of senior clinical team leaders, Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez, Vice President, Clinical Pharmacology, as well as the e.
- 10/01/2024
|
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”
- Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”. Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”.
- 09/27/2024
|
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin's Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 26, 2024. T.
- 09/24/2024
|
Cybin Provides Corporate Update on Upcoming Clinical Milestones
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones. “We are making rapid advancements in our two lead clinical programs – CYB003, our proprietary deuterated psilocin program in development for the.
- 09/19/2024
|
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
- Cybin's CYB003 and CYB004 programs show promising results in treating depression and anxiety, with CYB003 achieving 75% remission in Phase 2 trials. Phase 3 trials, leveraging a strong IP portfolio and a streamlined operational structure.
- 09/19/2024
|
Cybin Announces Completion of Previously Announced Share Consolidation
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company's issued and outstanding common shares (the “Common Shares”) on the basis of one new Common Share for every 38 existing Common Shares (the.
- 09/19/2024
|
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on August 27, 2024 (the “Meeting”). There were 87 shareholders represented in person or.
- 08/27/2024
|
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
- Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
- 08/12/2024
|
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, taking place August 13-14, 2024 in Boston, MA. Mr. Drysdale's.
- 08/07/2024
|
3 Biotech Stocks That Could Make Your Summer Unforgettable
- If you want to do well with biotech stocks, trade the anticipation of news. Look at Structure Therapeutics (NASDAQ: GPCR ), for example.
- 07/30/2024
|
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update
- Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser, Cybin highlighted key advancements that strengthened its position as a leader in developing next-generation psychedelic-based therapeutics.
- 07/08/2024
|
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
- While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.
- 07/02/2024
|
What Makes Cybin Inc. (CYBN) a New Buy Stock
- Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 06/27/2024
|
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental health disorders, today reported audited financial results for its fiscal year ended March 31, 2024, and recent business highlights. “I am proud of the swift and meaningful progress we have made advancing our two lead programs – C.
- 06/26/2024
|
Cilo Cybin becomes first medical cannabis company to list in South Africa
- South Africa's Cilo Cybin on Tuesday became the first medical cannabis company to list on the Johannesburg Stock Exchange's Alternative Exchange, as it hopes to capitalise on growth in the legal marijuana industry.
- 06/25/2024
|
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking place June 27, 2024. Mr. Drysdale's.
- 06/19/2024
|
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
- Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 06/11/2024
|
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program, Cybin's prop.
- 06/11/2024
|
Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder
- Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - In a significant stride towards transforming mental health care, Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) has proudly announced that its research site, Cedar Clinical Research (CCR), has been selected for Cybin's Phase 3 pivotal multinational clinical trial of CYB003. Aimed at revolutionizing the treatment of Major Depressive Disorder (MDD), this collaboration marks a pivotal moment in the journey toward understanding and treating one of the most debilitating mental health conditions affecting over 20 million Americans.
- 05/30/2024
|
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin's Chief Medical Officer, and Ellen James, Ph.D., Cybin's Director, Clinical Development, will participate at the Interdisciplinary Conference on Psychedelic.
- 05/29/2024
|
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2024. Mr. Drysdale's prese.
- 05/14/2024
|
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. “With the prevalence and burden of mental health conditions at an all-time high, there is.
- 05/06/2024
|
Cybin to Participate at the 27th Annual Milken Institute Global Conference
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled “Collaborating for Improved Mental Health.” The Conference wil.
- 04/25/2024
|
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that its research manuscript, entitled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-a.
- 04/18/2024
|
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder (“MDD”). The patent, which is expected to provide exclusiv.
- 04/16/2024
|
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, taking place April 16-17, 2024 in Toronto, Ontario. Mr. Drysdale's prese.
- 04/10/2024
|
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
- When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?
- 03/26/2024
|
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce the closing of the Company's previously announced private placement (the “Private Placement”) of 348,837,210 common shares in the capital of the Company (the “Common Shares”) at a price of U.S.$0.43.
- 03/19/2024
|
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
- Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
- 03/18/2024
|
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief Executive Officer of Cybin will participate in a fireside chat at the event and will be avai.
- 03/18/2024
|
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary DMT molecule in development for the treatment of GAD. In January 2024, the U.S. Food and Drug Administration (“FDA”) cleared Cyb.
- 03/15/2024
|
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder (“MDD”). This program will be the first ever adjunctive.
- 03/14/2024
|
Announces Oversubscribed Private Placement of U.S. $150 Million
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce a proposed private placement (the “Private Placement”) of 348,837,210 common shares in the capital of the Company (the “Common Shares”) at a price of U.S.$0.43 per Common Share representing a premium.
- 03/13/2024
|
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the FDA has granted BTD to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD. If approved by the FDA, CYB003 would be the first known adjunctive ps.
- 03/13/2024
|
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8:30 a.m. ET on Wednesday, March 13, 2024. The Company will provide a program update on CYB003, its proprietary deuterated psilocybin analog in development.
- 03/12/2024
|
3 High-Potential Penny Stocks to Turn $1000 into $1 million
- Investing in penny stocks requires not just patience, but an immense appetite for risk. U.S. equities are in the midst of a rally with the Nasdaq and S&P500 rising 7.97% and 7.02%, respectively, on a year-to-date basis.
- 03/10/2024
|
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024 in Boston, MA. Mr. Drysdale's presentation will be webcast.
- 02/27/2024
|
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today reported unaudited financial results for its third quarter ended December 31, 2023, and recent business highlights. “During the past three months, we have continued to make exciting progress with positive topline data from.
- 02/14/2024
|
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the Japan Patent (“JP”) Office has granted JP patents 2023-500532 and 2023-533436. The patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection.
- 02/07/2024
|
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug (“IND”) application for CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the tr.
- 01/23/2024
|
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
- Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
- 01/11/2024
|
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
- Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged lockdowns struggled with isolation as well as the threat of a deadly virus.
- 12/14/2023
|
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its abstract describing a comprehensive structure-activity relationship study of a series of novel serotonergic phenethylamines has been selected for presentation at the Neuropsychiatric Drug Development Summit taking pla.
- 10/06/2023
|
Cybin to Participate in the Cantor Global Healthcare Conference
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Chief Executive Officer of Cybin, and George Tziras, Chief Executive Officer of Small Pharma Inc., will participate in a panel discussion titled “Emerging Therapeutic Candidates for Mental Health” at.
- 09/25/2023
|
Cybin Announces Date of Annual and Special Meeting of Shareholders
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET. The notice of annual and special meeting and proxy statement containing meeting details are availab.
- 09/21/2023
|
Cybin shares continue to rise on major investment from Steve Cohen's hedge fund
- Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares maintained upward momentum on Wednesday after soaring earlier this week on the news New York Mets owner Steve Cohen's hedge fund Point72 Asset Management has taken an 8.1% stake in the biotechnology firm. Cybin stock added 39.4% at Monday's close after it was revealed Point72 had purchased almost 19 million shares of the company.
- 09/20/2023
|
Psychedelic stock jumps as Steve Cohen's Point72 snaps up shares
- Shares of Cybin Inc., CYBN, +39.39% a developer of psychedelic therapies, finished 38.5% higher on Monday after billionaire investor and New York Mets owner Steve Cohen's hedge fund Point72 disclosed that it had bought nearly 19 million shares of the company for an 8.1% stake. The filing was disclosed Friday and first noted on social media.
- 09/18/2023
|
Cybin skyrockets as Steve Cohen's hedge fund Point72 purchases almost 19M shares
- Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares added more than 19% Monday afternoon on the news that billionaire investor Steve Cohen's hedge fund Point72 Asset Management purchased almost 19 million shares in the biotechnology company which is developing psychedelics-based therapies for major depressive disorder and anxiety. Per a September 14 regulatory filing with the Securities Exchange Commission (SEC), the firm purchased 18,950,000 shares of Cybin, representing an 8.1% stake.
- 09/18/2023
|
The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023
- The global inflation surge and monetary policy tightening by major central banks have all contributed to the market volatility this year. Despite that, both the S&P 500 and the Nasdaq indices have returned 17.7% and 34.06% year-to-date, respectively.
- 09/14/2023
|
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
- Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.
- 07/16/2023
|
10 Top Penny Stocks To Watch Right Now For Under $1
- Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.
- 06/29/2023
|
Cybin narrows net loss year-over-year; eyes FDA submission in late 2023
- Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) reported that it has narrowed its net loss year-over-year as it has advanced its two lead clinical programs CYB003 and CYB004 during the 2023 fiscal year. For the fiscal year ended on March 31, 2023, the psychedelics-focused clinical-stage biopharmaceutical company posted a net loss of C$47.5 million, down from C$67.6 million in the previous fiscal year.
- 06/29/2023
|
FDA issues guidance on psychedelic drug clinical trials
- The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies investigating the drugs' potential to treat psychiatric and substance-use disorders and other medical conditions. Psychedelics are increasingly drawing attention from researchers, biotech companies and investors interested in their potential to help address the U.S. mental-health crisis.
- 06/23/2023
|
Best Penny Stocks to Buy Under $1? 10 To Watch Now
- Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1.
- 06/22/2023
|
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.
- Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive interview. The money will help fund academic institutions investigating psychedelics' potential to treat anxiety, depression, post-traumatic stress disorder and other mental-health issues, as well as nonprofits helping to connect patients in need with psychedelic treatments.
- 06/21/2023
|
Best Penny Stocks to Buy Under $1? 7 To Watch Now
- Typically, we refer to stocks trading for less than $5 per share, as penny stocks. However, for this article, we're focusing specifically on penny stocks under $1.
- 06/16/2023
|
Best Penny Stocks to Buy Under $1? 4 To Watch Now
- Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of penny stocks under $1.
- 06/15/2023
|
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
- Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year.
- 03/22/2023
|
Top 3 stocks under $1 to buy in March
- With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, leaving investors to wonder which stocks are worthy of their attention but often disregarding those obtainable for less than a dollar.
- 03/14/2023
|
Cybin shares rise as 3Q results meet expectations, analysts maintain ‘positive bias outlook'
- Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares moved higher just after the market opened on Wednesday after the psychedelics-focused biopharmaceutical company posted fiscal 2023 third quarter results in line with expectations and indicated a year-plus of cash runway. Cybin's Canadian-listed shares had added 5.6% at C$0.57, while its US-listed stock added 1.2% at US$0.42.
- 02/15/2023
|
The 7 Most Promising Psychedelic Stocks to Buy in February
- Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
- 02/05/2023
|
Psychedelic Sunday: Competitive Strategies
- Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
- 01/15/2023
|
Scrutinizing Psychedelic Stocks
- What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
- 01/08/2023
|
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
- Atai, Biogen, and Sage are working to develop new treatments for mental illness.
- 12/06/2022
|
Cybin: A Leading Early-Stage Psychedelics Play
- Cybin has the technologies, intellectual property, and funding it needs to advance its flagship pipeline project and continue being a leader in the psychedelics space. There are a pair of catalysts coming in the next few months, and both imply significant upsides.
- 11/23/2022
|
Mindset Pharma provides strategic intellectual property license to Cybin for preclinical psychedelic drug research
- Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced an exclusive licensing agreement for Cybin Inc to acquire intellectual property rights for a subset of Mindset's preclinical compounds. Under the terms of the agreement, biopharmaceutical company Cybin will license intellectual property related to preclinical compounds within Mindset's Family 1 portfolio, excluding MSP-1014, Mindset's lead psychedelic drug candidate.
- 09/27/2022
|
7 Psychedelics Stocks to Buy for a Big Drug Boom
- Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.
- 08/30/2022
|
Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week
- Hot biotech penny stocks to watch thanks to MNMD stock today. The post Penny Stocks To Buy Now?
- 08/18/2022
|
3 Best Psychedelic Stocks to Buy Now
- The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.
- 08/09/2022
|
Hot Penny Stocks to Watch Before Market Open on August 1st
- Here's what you need to know about trading penny stocks on August 1st The post Hot Penny Stocks to Watch Before Market Open on August 1st appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/01/2022
|
The Growth Potential Of Psychedelics Stocks And ETFs
- On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.
- 07/28/2022
|
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
- Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.
- 06/28/2022
|
Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving
- Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/27/2022
|
Penny Stocks To Buy Now? 4 To Watch Under $1
- Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?
- 05/23/2022
|
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at the KCSA Psychedelics Virtual Investor Conference at 11:00 a.m. ET on Thursday, April 28, 2022. This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. To participate
- 04/22/2022
|
Interested in Investing in Psychedelics? Check Out This Podcast.
- And other market news.
- 04/19/2022
|
Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today
- Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?
- 04/13/2022
|
Cybin, Deepak Chopra Announce Partnership For Psychedelics Awareness And Education
- Psychedelics-focused biotech company Cybin Inc. (NYSE:CYBN) announced that it has formed a partnership with The Chopra Foundation, a not-for-profit founded by alternative medicine and new age author Deepak Chopra. "The Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health,” the organization stated in a press release.
- 02/15/2022
|
Cybin to Participate in Aegis Virtual Conference on February 24, 2022
- TORONTO--(BUSINESS WIRE)--Cybin to Participate in Aegis Virtual Conference on February 24, 2022
- 02/15/2022
|
Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event
- Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube via The Psychedelic Investor channel, and will be moderated by James Hallifax, journalist and content director for Psychedelic Spotlight.
- 02/14/2022
|
Cybin, Inc. (CYBN) CEO Douglas Drysdale on Q3 2022 Results - Earnings Call Transcript
- Cybin, Inc. (CYBN) CEO Douglas Drysdale on Q3 2022 Results - Earnings Call Transcript
- 02/10/2022
|
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
- Psychedelics company Cybin Inc. CYBN CYBN announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company's investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT.
- 02/09/2022
|
Cilo Cybin Founder Gabriel Theron Plans First African Cannabis SPAC
- Africa's first cannabis-focused blank check company should list this year, aiming to acquire companies in a young industry, next to genetics and wearable health-device businesses reported Bloomberg. The founder of South Africa's Cilo Cybin Pharmaceutical Ltd, Gabriel Theron, told Bloomberg his plans to sell shares in a special purpose acquisition company in Johannesburg this spring with the goal of raising at least 500 million rands ($32 million).
- 02/08/2022
|
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
- TORONTO--(BUSINESS WIRE)--Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
- 01/27/2022
|
5 Psychedelic Therapeutics Decisions Coming in 2022
- Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.
- 01/25/2022
|
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
- On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ:FTRP) received a notice of allowance for a US patent application covering FT-104, its flagship psychedelic drug candidate.
- 01/11/2022
|
Why Cybin Shares Are Rising
- Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel Flow technology to measure psychedelic effects on the brain. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Doug Drysdale, Cybin's Chief Executive Officer.
- 01/11/2022
|
9 Psychedelic Stocks to Watch For 2022
- The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.
- 12/06/2021
|
Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress
- The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The trial will be conducted at the University of Washington.
- 11/30/2021
|
Cybin, Inc. (CYBN) CEO Doug Drysdale on Q2 2022 Results - Earnings Call Transcript
- Cybin, Inc. (CYBN) CEO Doug Drysdale on Q2 2022 Results - Earnings Call Transcript
- 11/15/2021
|
Cybin Reports Q2 Financial Results And Latest Business Highlights
- Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited financial results on Monday for the second quarter ended September 30, 2021. Second-Quarter Financial Highlights
- 11/15/2021
|
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser
- This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used to speak about only in whispers is now standard policy," says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.
- 11/14/2021
|
Cybin to Present at the Jefferies London Healthcare Conference
- TORONTO--(BUSINESS WIRE)--Cybin to Present at the Jefferies London Healthcare Conference
- 11/11/2021
|
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
- Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive pre-clinical data, indicating that its drug, CYB003 showed strong signs of cognitive improvement in patients with Major Depressive Disorder (MDD). Cybin chemically engineered and developed CYB003 to address some of the shortcomings of oral psilocybin as a treatment for mental health, including slow onset, high variability and short duration of action.
- 11/08/2021
|
Why Cybin Stock Is Down on Monday
- Positive pre-clinical data for CYB003 isn't nearly as exciting as investors hoped it would be.
- 11/08/2021
|
Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules
- Cybin Inc. (NYSE:CYBN) a company developing novel psychedelic compounds for therapeutic use, has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (DEA). The DEA license is a federal requirement for any investigators intending to study, produce or analyze Schedule I substances.
- 11/04/2021
|
